There have been significant trades of shares involving Everstar Asset Management, NewEdge Advisors, Curi RMB Capital, Voleon Capital Management and AQR Capital Management among others in Edwards Lifesciences Corporation. Multiple firms have been reducing their holdings, while others like Hawk Ridge Capital Management have significantly increased their stake. Amidst this trading activity, Edwards has shown strong sales growth and had a focus on stock repurchases. Despite strong full-year growth reports, some analysts argue that the share price of the corporation is not adding up. Furthermore, FTC seeks to block Edwards Lifesciences' acquisition of JenaValve. However, the company continues to perform well in its sector, outperforming several competitors on certain trading days. Substantial stock positions held by BNP Paribas Financial Markets, Corebridge Financial, and Vident Advisory indicate the faith investment firms have in the corporation. Nevertheless, some analysts have projected sluggish price action for the company's stock through 2027 and queries on whether the stock should remain in portfolios.
Edwards Lifesciences Corp EW News Analytics from Mon, 02 Dec 2024 08:00:00 GMT to Sat, 13 Sep 2025 17:37:24 GMT - Rating 4 - Innovation 3 - Information 7 - Rumor -5
